Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KURA
- Price
- 5.85
- Stock movement up
- +0.39 (5.53%)
- Company name
- Kura Oncology Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 645.77M
- Ent value
- 651.36M
- Price/Sales
- 508.48
- Price/Book
- 1.52
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 3.94%
- 1 year return
- -63.02%
- 3 year return
- -22.28%
- 5 year return
- -18.73%
- 10 year return
- -
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
KURA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 508.48 |
| Price to Book | 1.52 |
| EV to Sales | 512.88 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 86.80M |
| EPS (TTM) | -2.27 |
| FCF per share (TTM) | -1.95 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.27M |
| Gross profit (TTM) | 620.00K |
| Operating income (TTM) | -217.50M |
| Net income (TTM) | -197.55M |
| EPS (TTM) | -2.27 |
| EPS (1y forward) | -2.20 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 48.82% |
| Operating margin (TTM) | -17126.14% |
| Profit margin (TTM) | -15555.28% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 49.48M |
| Net receivables | 0.00 |
| Total current assets | 463.19M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 10.48M |
| Total assets | 478.84M |
| Accounts payable | 3.01M |
| Short/Current long term debt | 16.63M |
| Total current liabilities | 40.37M |
| Total liabilities | 55.07M |
| Shareholder's equity | 423.77M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -169.12M |
| Capital expenditures (TTM) | 116.00K |
| Free cash flow (TTM) | -169.24M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -46.62% |
| Return on Assets | -41.26% |
| Return on Invested Capital | -45.42% |
| Cash Return on Invested Capital | -38.91% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7.00 |
| Daily high | 7.68 |
| Daily low | 6.95 |
| Daily Volume | 2.35M |
| All-time high | 41.62 |
| 1y analyst estimate | 27.00 |
| Beta | 0.40 |
| EPS (TTM) | -2.27 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 30 Oct 2025 |
Downside potential
Loading...
Downside potential data
| KURA | S&P500 | |
| Current price drop from All-time high | -82.12% | -1.46% |
| Highest price drop | -87.15% | -56.47% |
| Date of highest drop | 5 Jul 2016 | 9 Mar 2009 |
| Avg drop from high | -51.80% | -10.99% |
| Avg time to new high | 59 days | 12 days |
| Max time to new high | 1178 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
645.77M
Marketcap category
Small-cap
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
Employees
192
Website
Investor relations
-
SEC filings
CEO
Troy E. Wilson
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page